Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1189525

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1189525

Global Acute LymphocyticLymphoblastic Leukemia (ALL) Diagnostics Market

PUBLISHED:
PAGES: 444 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 4800
PDF (Enterprise License) - Printable/Downloadable
USD 7000

Add to Cart

Description

Table of Contents

List of Tables

The global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market is projected to register a substantial CAGR of 7.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030

Market Segmentation:

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

Rise in prevalence and incidence of leukemia cancer

Increase in awareness about the leukemia cancer diagnostics

Market Players:

Some of the major players operating in the global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

QIAGEN

Abbott

Siemens Medical Solutions USA, Inc.

Merck KGaA

Hologic, Inc.

Agilent Technologies, Inc.

DiaSorin S.p.A.

Illumina, Inc.

bioMerieux SA

Myriad Genetics, Inc.

Quest Diagnostics Incorporated.

Bio-Rad Laboratories, Inc.

Koninklijke Philips N.V.

BD

Exact Sciences Corporation

Time Medical Holding

PlexBio

Michelson Diagnostics Ltd.

MinFound Medical Systems Co., Ltd

Medonica Co. LTD

SternMed GmbH

Show more

TABLE OF CONTENTS

1 INTRODUCTION 55

  • 1.1 OBJECTIVES OF THE STUDY 55
  • 1.2 MARKET DEFINITION 55
  • 1.3 OVERVIEW OF GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 55
  • 1.4 LIMITATIONS 57
  • 1.5 MARKETS COVERED 58

2 MARKET SEGMENTATION 61

  • 2.1 MARKETS COVERED 61
  • 2.2 GEOGRAPHICAL SCOPE 62
  • 2.3 YEARS CONSIDERED FOR THE STUDY 63
  • 2.4 CURRENCY AND PRICING 63
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 64
  • 2.6 MULTIVARIATE MODELLING 67
  • 2.7 PRODUCT TYPE LIFELINE CURVE 67
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
  • 2.9 DBMR MARKET POSITION GRID 69
  • 2.10 MARKET TESTING TYPE COVERAGE GRID 71
  • 2.11 VENDOR SHARE ANALYSIS 72
  • 2.12 SECONDARY SOURCES 73
  • 2.13 ASSUMPTIONS 73

3 EXECUTIVE SUMMARY 74

4 PREMIUM INSIGHTS 77

  • 4.1 PESTEL ANALYSIS 81
  • 4.2 PORTER'S FIVE FORCES 82
  • 4.3 INDUSTRY INSIGHTS 83

5 EPIDEMIOLOGY 85

6 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 86

7 MARKET OVERVIEW 89

  • 7.1 DRIVERS 91
    • 7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 91
    • 7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 91
    • 7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 92
    • 7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 92
  • 7.2 RESTRAINTS 94
    • 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 94
    • 7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 95
  • 7.3 OPPORTUNITIES 95
    • 7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 95
    • 7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 96
    • 7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 96
  • 7.4 CHALLENGES 97
    • 7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 97
    • 7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 98

8 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 99

  • 8.1 OVERVIEW 100
  • 8.2 INSTRUMENTS 103
    • 8.2.1 BIOPSY INSTRUMENTS 104
      • 8.2.1.1 BONE MARROW BIOPSY 104
      • 8.2.1.2 NEEDLE BIOPSY 104
      • 8.2.1.3 SURGEON BIOPSY 105
      • 8.2.1.4 OTHERS 105
    • 8.2.2 PATHOLOGY-BASED INSTRUMENTS 105
      • 8.2.2.1 PCR INSTRUMENTS 105
      • 8.2.2.2 SLIDE STAINING SYSTEMS 105
      • 8.2.2.3 TISSUE PROCESSING SYSTEMS 105
      • 8.2.2.4 CELL PROCESSORS 106
      • 8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 106
    • 8.2.3 IMAGING INSTRUMENTS 106
      • 8.2.3.1 ULTRASOUND SYSTEMS 106
      • 8.2.3.2 CT SYSTEMS 106
      • 8.2.3.3 MRI SYSTEMS 106
      • 8.2.3.4 OTHERS 107
    • 8.2.4 OTHERS 107
  • 8.3 CONSUMABLES & ACCESSORIES 107
    • 8.3.1 KITS 108
      • 8.3.1.1 PCR KITS 108
      • 8.3.1.2 DNA POLYMERASE KITS 108
      • 8.3.1.3 NUCLEIC ACID ISOLATION KITS 108
      • 8.3.1.4 OTHERS 109
    • 8.3.2 REAGENTS 109
      • 8.3.2.1 ASSAYS 109
      • 8.3.2.2 BUFFERS 109
      • 8.3.2.3 PRIMERS 109
      • 8.3.2.4 OTHERS 109
    • 8.3.3 PROBES 110
    • 8.3.4 OTHER CONSUMABLES 110

9 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 111

  • 9.1 OVERVIEW 112
  • 9.2 BIOPSY 115
    • 9.2.1 BONE MARROW BIOPSY 116
    • 9.2.2 NEEDLE BIOPSY 116
    • 9.2.3 SURGEON BIOPSY 116
    • 9.2.4 OTHERS 116
  • 9.3 BLOOD TEST 117
    • 9.3.1 BLOOD CHEMISTRY TESTS 118
    • 9.3.2 COMPLETE BLOOD COUNT (CBC) 118
    • 9.3.3 OTHERS 118
  • 9.4 IMAGING TEST 118
    • 9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 119
    • 9.4.2 MRI 119
    • 9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 120
    • 9.4.4 OTHERS 120
  • 9.5 OTHERS 120

10 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 121

  • 10.1 OVERVIEW 122
  • 10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 125
    • 10.2.1 EARLY PRE-B ALL 126
    • 10.2.2 COMMON ALL 126
    • 10.2.3 PRE-B ALL 126
    • 10.2.4 MATURE B-CELL ALL 126
  • 10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 126
    • 10.3.1 PRE-T ALL 127
    • 10.3.2 MATURE T-CELL ALL 127

11 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 128

  • 11.1 OVERVIEW 129
  • 11.2 BELOW 21 132
  • 11.3 21-29 133
  • 11.4 30-65 134
  • 11.5 65 AND ABOVE 135

12 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 136

  • 12.1 OVERVIEW 137
  • 12.2 MALE 140
  • 12.3 FEMALE 141

13 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 142

  • 13.1 OVERVIEW 143
  • 13.2 HOSPITALS 146
  • 13.3 ASSOCIATED LABS 146
  • 13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 147
  • 13.5 DIAGNOSTIC IMAGING CENTERS 148
  • 13.6 CANCER RESEARCH INSTITUTES 148
  • 13.7 OTHERS 149

14 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 150

  • 14.1 OVERVIEW 151
  • 14.2 DIRECT TENDER 154
  • 14.3 RETAIL SALES 155

15 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 156

  • 15.1 OVERVIEW 157
  • 15.2 NORTH AMERICA 163
    • 15.2.1 U.S. 175
    • 15.2.2 CANADA 181
    • 15.2.3 MEXICO 187
  • 15.3 EUROPE 193
    • 15.3.1 GERMANY 204
    • 15.3.2 FRANCE 211
    • 15.3.3 U.K. 218
    • 15.3.4 ITALY 224
    • 15.3.5 RUSSIA 230
    • 15.3.6 SPAIN 237
    • 15.3.7 NETHERLANDS 243
    • 15.3.8 SWITZERLAND 249
    • 15.3.9 TURKEY 255
    • 15.3.10 BELGIUM 261
    • 15.3.11 REST OF EUROPE 267
  • 15.4 ASIA-PACIFIC 268
    • 15.4.1 CHINA 279
    • 15.4.2 JAPAN 284
    • 15.4.3 INDIA 289
    • 15.4.4 AUSTRALIA 294
    • 15.4.5 INDONESIA 299
    • 15.4.6 SOUTH KOREA 304
    • 15.4.7 VIETNAM 310
    • 15.4.8 THAILAND 315
    • 15.4.9 PHILIPPINES 320
    • 15.4.10 MALAYSIA 325
    • 15.4.11 SINGAPORE 330
    • 15.4.12 REST OF ASIA PACIFIC 335
  • 15.5 SOUTH AMERICA 336
    • 15.5.1 BRAZIL 347
    • 15.5.2 ARGENTINA 352
    • 15.5.3 REST OF SOUTH AMERICA 358
  • 15.6 MIDDLE EAST AND AFRICA 359
    • 15.6.1 SOUTH AFRICA 370
    • 15.6.2 EGYPT 375
    • 15.6.3 SAUDI ARABIA 380
    • 15.6.4 ISRAEL 385
    • 15.6.5 UAE 390
    • 15.6.6 REST OF MIDDLE EAST AND AFRICA 395

16 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 396

  • 16.1 COMPANY SHARE ANALYSIS: GLOBAL 396
  • 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 397
  • 16.3 COMPANY SHARE ANALYSIS: EUROPE 398
  • 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 399

17 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 400

  • 17.1 F. HOFFMANN-LA ROCHE LTD. 400
    • 17.1.1 COMPANY SNAPSHOT 400
    • 17.1.2 REVENUE ANALYSIS 400
    • 17.1.3 COMPANY SHARE ANALYSIS 401
    • 17.1.4 PRODUCT PORTFOLIO 401
    • 17.1.5 RECENT DEVELOPMENT 401
  • 17.2 THERMO FISHER SCIENTIFIC INC. 402
    • 17.2.1 COMPANY SNAPSHOT 402
    • 17.2.2 REVENUE ANALYSIS 402
    • 17.2.3 COMPANY SHARE ANALYSIS 403
    • 17.2.4 PRODUCT PORTFOLIO 403
    • 17.2.5 RECENT DEVELOPMENT 403
  • 17.3 QIAGEN 404
    • 17.3.1 COMPANY SNAPSHOT 404
    • 17.3.2 REVENUE ANALYSIS 404
    • 17.3.3 COMPANY SHARE ANALYSIS 405
    • 17.3.4 PRODUCT PORTFOLIO 405
    • 17.3.5 RECENT DEVELOPMENT 405
  • 17.4 ABBOTT 406
    • 17.4.1 COMPANY SNAPSHOT 406
    • 17.4.2 REVENUE ANALYSIS 406
    • 17.4.3 COMPANY SHARE ANALYSIS 407
    • 17.4.4 PRODUCT PORTFOLIO 407
    • 17.4.5 RECENT DEVELOPMENT 407
  • 17.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 408
    • 17.5.1 COMPANY SNAPSHOT 408
    • 17.5.2 REVENUE ANALYSIS 408
    • 17.5.3 COMPANY SHARE ANALYSIS 409
    • 17.5.4 PRODUCT PORTFOLIO 409
    • 17.5.5 RECENT DEVELOPMENT 409
  • 17.6 MERCK KGAA 410
    • 17.6.1 COMPANY SNAPSHOT 410
    • 17.6.2 REVENUE ANALYSIS 410
    • 17.6.3 PRODUCT PORTFOLIO 411
    • 17.6.4 RECENT DEVELOPMENT 411
  • 17.7 HOLOGIC INC. 412
    • 17.7.1 COMPANY SNAPSHOT 412
    • 17.7.2 REVENUE ANALYSIS 412
    • 17.7.3 PRODUCT PORTFOLIO 413
    • 17.7.4 RECENT DEVELOPMENT 413
  • 17.8 AGILENT TECHNOLOGIES, INC. 414
    • 17.8.1 COMPANY SNAPSHOT 414
    • 17.8.2 REVENUE ANALYSIS 414
    • 17.8.3 PRODUCT PORTFOLIO 415
    • 17.8.4 RECENT DEVELOPMENT 415
  • 17.9 BD 416
    • 17.9.1 COMPANY SNAPSHOT 416
    • 17.9.2 REVENUE ANALYSIS 416
    • 17.9.3 PRODUCT PORTFOLIO 417
    • 17.9.4 RECENT DEVELOPMENT 417
  • 17.10 BIOMERIEUX SA 418
    • 17.10.1 COMPANY SNAPSHOT 418
    • 17.10.2 REVENUE ANALYSIS 418
    • 17.10.3 PRODUCT PORTFOLIO 419
    • 17.10.4 RECENT DEVELOPMENTS 419
  • 17.11 BIO-RAD LABORATORIES, INC. 420
    • 17.11.1 COMPANY SNAPSHOT 420
    • 17.11.2 REVENUE ANALYSIS 420
    • 17.11.3 PRODUCT PORTFOLIO 421
    • 17.11.4 RECENT DEVELOPMENT 421
  • 17.12 DIASORIN S.P.A. 422
    • 17.12.1 COMPANY SNAPSHOT 422
    • 17.12.2 REVENUE ANALYSIS 422
    • 17.12.3 PRODUCT PORTFOLIO 423
    • 17.12.4 RECENT DEVELOPMENTS 423
  • 17.13 EXACT SCIENCE CORPORATION 424
    • 17.13.1 COMPANY SNAPSHOT 424
    • 17.13.2 REVENUE ANALYSIS 424
    • 17.13.3 PRODUCT PORTFOLIO 425
    • 17.13.4 RECENT DEVELOPMENT 425
  • 17.14 ILLUMINA, INC. 426
    • 17.14.1 COMPANY SNAPSHOT 426
    • 17.14.2 REVENUE ANALYSIS 426
    • 17.14.3 PRODUCT PORTFOLIO 427
    • 17.14.4 RECENT DEVELOPMENT 427
  • 17.15 KONINKLIJKE PHILIPS N.V. 428
    • 17.15.1 COMPANY SNAPSHOT 428
    • 17.15.2 REVENUE ANALYSIS 428
    • 17.15.3 PRODUCT PORTFOLIO 429
    • 17.15.4 RECENT DEVELOPMENT 429
Show more
  • 17.16 MEDONICA CO. LTD 430
    • 17.16.1 COMPANY SNAPSHOT 430
    • 17.16.2 PRODUCT PORTFOLIO 430
    • 17.16.3 RECENT DEVELOPMENT 430
  • 17.17 MICHAEL DIAGNOSTICS LTD 431
    • 17.17.1 COMPANY SNAPSHOT 431
    • 17.17.2 PRODUCT PORTFOLIO 431
    • 17.17.3 RECENT DEVELOPMENT 431
  • 17.18 MINFOUND MEDICAL SYSTEMS CO., LTD 432
    • 17.18.1 COMPANY SNAPSHOT 432
    • 17.18.2 PRODUCT PORTFOLIO 432
    • 17.18.3 RECENT DEVELOPMENT 432
  • 17.19 MYRIAD GENETICS, INC. 433
    • 17.19.1 COMPANY SNAPSHOT 433
    • 17.19.2 REVENUE ANALYSIS 433
    • 17.19.3 PRODUCT PORTFOLIO 434
    • 17.19.4 RECENT DEVELOPMENT 434
  • 17.20 PLEXBIO 435
    • 17.20.1 COMPANY SNAPSHOT 435
    • 17.20.2 PRODUCT PORTFOLIO 435
    • 17.20.3 RECENT DEVELOPMENTS 435
  • 17.21 QUEST DIAGNOSTICS INCORPORATED 436
    • 17.21.1 COMPANY SNAPSHOT 436
    • 17.21.2 REVENUE ANALYSIS 436
    • 17.21.3 PRODUCT PORTFOLIO 437
    • 17.21.4 RECENT DEVELOPMENTS 437
  • 17.22 STERNMED GMBH 438
    • 17.22.1 COMPANY SNAPSHOT 438
    • 17.22.2 PRODUCT PORTFOLIO 438
    • 17.22.3 RECENT DEVELOPMENTS 438
  • 17.23 TIME MEDICAL HOLDING 439
    • 17.23.1 COMPANY SNAPSHOT 439
    • 17.23.2 PRODUCT PORTFOLIO 439
    • 17.23.3 RECENT DEVELOPMENT 439

18 QUESTIONNAIRE 440

19 RELATED REPORTS 444

LIST OF TABLES

  • TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 95
  • TABLE 2 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 3 GLOBAL INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
  • TABLE 4 GLOBAL INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 5 GLOBAL BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 6 GLOBAL PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 7 GLOBAL IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 8 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
  • TABLE 9 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 10 GLOBAL KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 11 GLOBAL REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 12 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 13 GLOBAL BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
  • TABLE 14 GLOBAL BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 15 GLOBAL BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
  • TABLE 16 GLOBAL BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 17 GLOBAL IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
  • TABLE 18 GLOBAL IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 19 GLOBAL OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
  • TABLE 20 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 21 GLOBAL B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
  • TABLE 22 GLOBAL B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 23 GLOBAL T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 24 GLOBAL T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 25 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 131
  • TABLE 26 GLOBAL BELOW 21 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 132
  • TABLE 27 GLOBAL 21-29 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
  • TABLE 28 GLOBAL 30-65 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
  • TABLE 29 GLOBAL 65 AND ABOVE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 30 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 139
  • TABLE 31 GLOBAL MALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 140
  • TABLE 32 GLOBAL FEMALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 141
  • TABLE 33 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 145
  • TABLE 34 GLOBAL HOSPITALS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 35 GLOBAL ASSOCIATED LABS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
  • TABLE 36 GLOBAL INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
  • TABLE 37 GLOBAL DIAGNOSTIC IMAGING CENTER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 38 GLOBAL CANCER RESEARCH INSTITUTES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 149
  • TABLE 39 GLOBAL OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 149
  • TABLE 40 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 153
  • TABLE 41 GLOBAL DIRECT TENDER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
  • TABLE 42 GLOBAL RETAIL SALES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 155
  • TABLE 43 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 162
  • TABLE 44 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 168
  • TABLE 45 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 46 NORTH AMERICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 47 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 48 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 49 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 50 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 51 NORTH AMERICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 52 NORTH AMERICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 53 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 54 NORTH AMERICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 55 NORTH AMERICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 56 NORTH AMERICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 57 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 58 NORTH AMERICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 59 NORTH AMERICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 60 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 173
  • TABLE 61 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 173
  • TABLE 62 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 174
  • TABLE 63 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 174
  • TABLE 64 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 65 U.S. INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 66 U.S. PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 67 U.S. IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 68 U.S. BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 69 U.S. CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 70 U.S. KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 71 U.S. REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 72 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 73 U.S. IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 74 U.S. BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 75 U.S. BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 76 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 77 U.S. B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 78 U.S. T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 79 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 180
  • TABLE 80 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 180
  • TABLE 81 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 180
  • TABLE 82 U.S. ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 180
  • TABLE 83 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 84 CANADA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 85 CANADA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 86 CANADA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 87 CANADA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 88 CANADA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 89 CANADA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 90 CANADA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 91 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 92 CANADA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 93 CANADA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 94 CANADA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 95 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 96 CANADA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 97 CANADA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 98 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 186
  • TABLE 99 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 186
  • TABLE 100 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 186
  • TABLE 101 CANADA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 186
  • TABLE 102 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 103 MEXICO INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 104 MEXICO PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 105 MEXICO IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 106 MEXICO BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 107 MEXICO CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 108 MEXICO KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 189
  • TABLE 109 MEXICO REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 189
  • TABLE 110 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 189
  • TABLE 111 MEXICO IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 112 MEXICO BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 113 MEXICO BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 114 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 115 MEXICO B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 116 MEXICO T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 117 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 192
  • TABLE 118 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 192
  • TABLE 119 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 192
  • TABLE 120 MEXICO ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 192
  • TABLE 121 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 198
  • TABLE 122 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 123 EUROPE INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 124 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 199

LIST OF FIGURES

  • FIGURE 1 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 61
  • FIGURE 2 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DATA TRIANGULATION 64
  • FIGURE 3 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DROC ANALYSIS 65
  • FIGURE 4 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 66
  • FIGURE 5 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 66
  • FIGURE 6 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 68
  • FIGURE 7 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 69
  • FIGURE 8 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID 71
  • FIGURE 9 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 72
  • FIGURE 10 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SEGMENTATION 76
  • FIGURE 11 INCREASE IN THE AWARENESS ABOUT LEUKEMIA IS EXPECTED TO DRIVE THE GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN THE FORECAST PERIOD 77
  • FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET IN 2023 & 2030 77
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 79
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD 80
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL ACUTE LYMPHOCYTIC/ LYMPHOBLASTIC (ALL) LEUKEMIA DIAGNOSTICS MARKET 90
  • FIGURE 16 GLOBAL LEUKEMIA INCIDENCE (BOTH SEXES) 93
  • FIGURE 17 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE (BOTH SEXES) 94
  • FIGURE 18 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 100
  • FIGURE 19 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 101
  • FIGURE 20 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 101
  • FIGURE 21 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY PRODUCT TYPE, LIFELINE CURVE 102
  • FIGURE 22 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2022 112
  • FIGURE 23 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 113
  • FIGURE 24 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 113
  • FIGURE 25 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 114
  • FIGURE 26 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 122
  • FIGURE 27 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 123
  • FIGURE 28 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 123
  • FIGURE 29 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 124
  • FIGURE 30 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2022 129
  • FIGURE 31 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 130
  • FIGURE 32 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 130
  • FIGURE 33 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 131
  • FIGURE 34 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2022 137
  • FIGURE 35 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 138
  • FIGURE 36 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 138
  • FIGURE 37 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY GENDER, LIFELINE CURVE 139
  • FIGURE 38 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2022 143
  • FIGURE 39 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 144
  • FIGURE 40 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 144
  • FIGURE 41 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 145
  • FIGURE 42 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 151
  • FIGURE 43 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 152
  • FIGURE 44 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 152
  • FIGURE 45 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 153
  • FIGURE 46 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 158
  • FIGURE 47 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY REGION (2022) 160
  • FIGURE 48 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 160
  • FIGURE 49 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 161
  • FIGURE 50 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023 - 2030) 161
  • FIGURE 51 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 164
  • FIGURE 52 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 166
  • FIGURE 53 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 166
  • FIGURE 54 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 167
  • FIGURE 55 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 167
  • FIGURE 56 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 194
  • FIGURE 57 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 196
  • FIGURE 58 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 196
  • FIGURE 59 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 197
  • FIGURE 60 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 197
  • FIGURE 61 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 269
  • FIGURE 62 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 271
  • FIGURE 63 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 271
  • FIGURE 64 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 272
  • FIGURE 65 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 272
  • FIGURE 66 SOUTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 337
  • FIGURE 67 SOUTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 339
  • FIGURE 68 SOUTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 339
  • FIGURE 69 SOUTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 340
  • FIGURE 70 SOUTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 340
  • FIGURE 71 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: SNAPSHOT (2022) 360
  • FIGURE 72 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022) 362
  • FIGURE 73 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 362
  • FIGURE 74 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 363
  • FIGURE 75 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 363
  • FIGURE 76 GLOBAL ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 396
  • FIGURE 77 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 397
  • FIGURE 78 EUROPE ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 398
  • FIGURE 79 ASIA-PACIFIC ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 399
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!